Inflammatory myofibroblastic tumor (IMT)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-IMT |
|---|---|
| Type | Disease |
| Aliases | IMTInflammatory myofibroblastic tumorInflammatory pseudotumor (historical, now distinct)Plasma cell granuloma (historical)Запальна міофібробластична пухлина |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-NSCLC-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8825/1 |
|---|---|
| icd_o_3_topography | ["C76", "C16", "C25", "C34", "C49", "C56"] |
| icd_10 | D48.1 |
| who_classification | WHO Soft Tissue Tumours 5th ed (2020): Inflammatory myofibroblastic tumour (intermediate, rarely metastasizing) |
Notes
Mesenchymal neoplasm of intermediate biological behavior — locally invasive, ~25% recurrence rate, <5% metastatic. Fusion-driven biology (ALK most common) makes IMT one of the few sarcomas with broadly actionable targets. Therapy: - Localized: complete surgical resection — curative in most. - Unresectable / metastatic ALK+: crizotinib FDA-approved (pediatric + adult); lorlatinib for crizotinib-resistant. - ROS1+: entrectinib (FDA tumor-agnostic) or crizotinib. - NTRK+: larotrectinib / entrectinib (FDA tumor-agnostic). - Fusion-negative: surgery, radiation, sometimes corticosteroids / NSAIDs (historical), or chemotherapy by sarcoma protocol. IMT is one of the canonical examples of "rare disease, common driver" — small absolute numbers but high actionable-fraction; supports a case for universal molecular profiling at diagnosis.
Used By
Algorithms
ALGO-IMT-1L- ALGO-IMT-1L
Indication
IND-IMT-ALK-CRIZOTINIB- IND-IMT-ALK-CRIZOTINIB
Questionnaires
QUEST-IMT-1L-STUB- Inflammatory myofibroblastic tumor — first line
Red flag
RF-IMT-FRAILTY-AGE- Age ≥75 with ECOG ≥2 or ≥2 comorbidities — methotrexate / vinorelbine cytotoxic adjuvant...RF-IMT-HIGH-RISK-BIOLOGY- Inflammatory myofibroblastic tumor with actionable fusion driver: ALK fusion (TPM3-ALK, T...RF-IMT-INFECTION-SCREENING- Active or latent infection requiring resolution / prophylaxis before initiating crizotini...RF-IMT-ORGAN-DYSFUNCTION- Baseline organ dysfunction precluding standard methotrexate / vinorelbine adjuvant or aff...RF-IMT-TRANSFORMATION-PROGRESSION- IMT progression on first-line crizotinib (acquired ALK kinase-domain resistance mutation...